Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy.

Cancer Lett

School of Medicine and Public Health, Department of Dermatology, University of Wisconsin-Madison, WI 53706, USA. Electronic address:

Published: August 2017

Melittin (MEL), a major peptide component of bee venom, is an attractive candidate for cancer therapy. This agent has shown a variety of anti-cancer effects in preclinical cell culture and animal model systems. Despite a convincing efficacy data against variety of cancers, its applicability to humans has met with challenges due to several issues including its non-specific cytotoxicity, degradation and hemolytic activity. Several optimization approaches including utilization of nanoparticle based delivery of MEL have been utilized to circumvent the issues. Here, we summarize the current understanding of the anticancer effects of bee venom and MEL on different kinds of cancers. Further, we also present the available information for the possible mechanism of action of bee venom and/or MEL.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682937PMC
http://dx.doi.org/10.1016/j.canlet.2017.05.010DOI Listing

Publication Analysis

Top Keywords

bee venom
16
major peptide
8
peptide component
8
component bee
8
cancer therapy
8
melittin major
4
bee
4
venom
4
venom conjugates
4
conjugates cancer
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!